Pulmonary Tuberculosis Today: Science, Strides and Solutions

Qeth Rbramson^*
*Correspondence: Qeth Rbramson, Department of Pharmacy, University of Pisa, 56126 Pisa, Italy, Email:

Introduction

Pulmonary Tuberculosis (TB) remains a significant global health concern despite considerable progress made in its diagnosis, treatment, and prevention. This infectious disease, primarily caused by the bacterium Mycobacterium tuberculosis, affects the lungs and is responsible for substantial morbidity and mortality worldwide. This comprehensive essay delves into the current state of pulmonary tuberculosis, exploring the scientific advancements, medical strides, and potential solutions that continue to shape our understanding and management of the disease. Tuberculosis is among the top ten causes of death worldwide, ranking alongside diseases such as HIV/AIDS and malaria. The World Health Organization (WHO) estimates that in 2020, there were approximately 10 million new cases of TB, with 1.5 million deaths attributed to the disease. The majority of TB cases and deaths occur in low- and middle-income countries, making it a pressing global health issue.

Description

While the burden of TB is distributed unevenly across the globe, it is not confined to developing nations. Even in high-income countries, TB remains a concern due to factors like migration, overcrowded living conditions, and inadequate healthcare access among vulnerable populations. The emergence of drug-resistant TB strains further complicates the management of the disease. To effectively address TB, it is crucial to understand the disease itself, including its causative agent, transmission, and pathogenesis. Mycobacterium tuberculosis is a slow-growing, aerobic, acid-fast bacterium. It is transmitted primarily through the inhalation of respiratory droplets containing the bacteria, released into the air when an infected individual coughs or sneezes.

Once inhaled, the bacteria can enter the lungs and initiate infection. The immune system's response leads to the formation of granulomas, which are small, organized structures designed to contain the bacteria. This often results in Latent TB Infection (LTBI), where the bacteria remain dormant within the granulomas. In some cases, the bacteria can break out of the granulomas, leading to active TB disease. The accurate diagnosis of TB is a critical first step in its management. Over the years, advancements in diagnostic methods have greatly improved our ability to detect and confirm TB cases. raditional microscopy, such as acid-fast staining, remains a common method for diagnosing TB, but it is relatively insensitive and unable to distinguish between different strains. Radiological imaging, particularly chest X-rays, is often used to identify pulmonary TB. However, it may not be definitive and can miss early or extra pulmonary cases [1].

Polymerase Chain Reaction (PCR) and other molecular tests have revolutionized TB diagnosis. GeneXpert, a widely used PCR-based technology, can quickly detect TB and its drug-resistant forms. This has greatly enhanced early diagnosis and improved treatment outcomes. Employs ultrasound waves to enhance the effect of thrombolytic agents, potentially reducing the required dose and associated bleeding risks. In cases of hemodynamic instability and failure to respond to conventional therapies, ECMO has emerged as a Promising Option. ECMO provides mechanical circulatory support, allowing the heart and lungs to rest while blood is oxygenated and circulated externally. This innovative approach can buy time for the patient to recover and for definitive treatment to take effect [2].

The treatment of TB is primarily antibiotic-based. The standard regimen involves a combination of antibiotics taken over an extended period. The most common drugs used include isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin. While treatment success rates are generally high, several factors complicate TB management. One major concern is the emergence of drug-resistant TB. Drug-resistant strains can be either Multidrug-Resistant (MDR-TB) or Extensively Drug-Resistant (XDR-TB). MDR-TB is resistant to the two most potent first-line drugs (isoniazid and rifampicin), while XDR-TB is resistant to these two drugs and at least one second-line drug. The development of drug-resistant TB is often linked to poor treatment adherence and healthcare infrastructure, as incomplete or incorrect treatment can lead to the survival and evolution of resistant strains. Managing drug-resistant TB is a formidable challenge, as it requires longer and more complex treatment regimens, often with more toxic drugs [3].

Scientific research has not stood still, and new drugs and treatment strategies are emerging. Bedaquiline and delamanid are two novel drugs approved for the treatment of MDR-TB. These drugs have shown promise in improving treatment outcomes and reducing the duration of therapy. Additionally, research into new drug candidates and regimens is ongoing, offering hope for better outcomes in the fight against drug-resistant TB. Preventing TB is as important as treating it, particularly in countries with a high disease burden. Several preventive measures and strategies have been developed and implemented to reduce TB transmission [4].

The Bacillus Calmette-Guérin (BCG) vaccine, developed in the 1920s, is the only licensed vaccine for TB. While it is not fully effective at preventing TB disease in adults, it is still widely administered, particularly in countries with high TB prevalence, to protect against severe forms of the disease in children. Individuals with LTBI are at risk of developing active TB. Treating LTBI with isoniazid or other regimens can reduce this risk. Infection Control: In healthcare settings, proper infection control measures can prevent TB transmission. This includes the use of N95 respirators, isolation of TB patients, and proper ventilation. Identifying and treating active TB cases in the community is essential. Contact tracing, screening, and community-based education are important components of public health interventions. Targeted Testing and Treatment: High-risk populations, such as those with HIV or close contacts of TB patients, should be targeted for testing and preventive treatment. The ongoing battle against TB has seen significant scientific advances, medical strides, and promising solutions emerge. As we conclude our exploration of pulmonary tuberculosis today, it is clear that we are in a position to make real progress in the fight against this ancient scourge.

Diagnostic methods have evolved, with rapid molecular tests becoming more accessible. These tools are crucial in identifying cases quickly, including drug-resistant strains, and ensuring timely treatment initiation. New diagnostic techniques and biomarkers offer hope for even more accurate and less invasive detection. In the realm of treatment, while drug-resistant TB continues to pose a formidable challenge, novel drugs like bedaquiline and delamanid are providing renewed optimism [5].

Conclusion

Researchers are diligently working on the development of new antibiotics, regimens, and even immunotherapies, opening doors to more effective treatments and shorter therapy durations. Preventive measures, including vaccination, treatment of latent TB infection, and robust public health interventions, are essential to reduce TB transmission and prevalence. Innovations in vaccine development, such as novel candidates in clinical trials, may one day provide us with a more potent weapon against TB. It's important to acknowledge that the fight against TB is not just about medical advancements. Social determinants of health, such as poverty, malnutrition, and lack of access to healthcare, continue to play a significant role in the disease's persistence. Solutions must extend beyond the laboratory and clinic to address these underlying issues. Pulmonary tuberculosis today is marked by scientific progress, medical strides, and an unwavering commitment to finding solutions. The global community's efforts to combat this ancient disease have yielded tangible results, but there is much work left to be done. We must maintain our vigilance, allocate resources, and continue to collaborate across borders and disciplines. With sustained dedication to research, prevention, and treatment, we can hope for a world where tuberculosis is a relic of the past, rather than a threat to our future.

Acknowledgement

None.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

1. Podojil, Joseph R and Stephen D. Miller. "Molecular mechanisms of T‐cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy." Immunol Rev 229 (2009): 337-355.

Google Scholar, Crossref, Indexed at

2. Boussiotis, Vassiliki A., Pranam Chatterjee and Lequn Li. "Biochemical signaling of PD-1 on T cells and its functional implications." Cancer J 20 (2014): 265.

Google Scholar, Crossref, Indexed at

3. Ahmadzadeh, Mojgan, Laura A. Johnson, Bianca Heemskerk and John R. Wunderlich, et al. "Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired." Blood 114 (2009): 1537-1544.

Google Scholar, Crossref, Indexed at

4. Lim, Tong Seng, Valerie Chew, Je Lin Sieow and Siting Goh, et al. "PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity." Oncoimmunology 5 (2016): e1085146.

Google Scholar, Crossref, Indexed at

5. Kinter, Audrey L., Emily J. Godbout, Jonathan P. McNally and Irini Sereti, et al. "The common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands." J Immunol 181 (2008): 6738-6746.

Google Scholar, Crossref, Indexed at